WO2010104485A2 - Valsartan formulations - Google Patents
Valsartan formulations Download PDFInfo
- Publication number
- WO2010104485A2 WO2010104485A2 PCT/TR2010/000046 TR2010000046W WO2010104485A2 WO 2010104485 A2 WO2010104485 A2 WO 2010104485A2 TR 2010000046 W TR2010000046 W TR 2010000046W WO 2010104485 A2 WO2010104485 A2 WO 2010104485A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- valsartan
- microcrystalline cellulose
- pregelatinized starch
- tablet
- silicon dioxide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Definitions
- the present invention relates to a new pharmaceutical formulation in the form of a tablet consisting of valsartan as an active agent, pregelatinized starch, microcrystalline cellulose.
- Valsartan a compound having the chemical name N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5- yl)[1 ,1 '-biphenyl]-4-yl]methyl]-L-valine, of formula I
- Valsartan belongs to the group of drugs that block receptors of angiotensin Il and thus cause a decrease of blood pressure.
- Presently valsartan tablets are marketed by Novartis as DIOVAN® in doses of 40, 80, 160 and 320 mg and it is used to treat hypertension.
- WO 9524901 A1 (CIBA-GEIGY AG) 07.03.1995, page 6 is directed to the use of valsartan for the treatment of diabetic nephropathy.
- a hard gelatine capsule comprising valsartan is disclosed.
- the described capsule dosage form above is prepared by below method. Valsartan and microcrystalline cellulose are granulated via wet granulation with solution of polyvidone and sodium lauryl sulphate in water. The granules are dried. Crospovidone and magnesium stearate are added to the dry granulate and the mixture is filled into capsules.
- the first fifth components above formulation are mixed and compacted at pressures 25 to 65 kN.
- the compacted material is further forced through a sieve.
- Granulate produced in this way is mixed with magnesium stearate and the mixture is compressed into tablets.
- WO 9749394 A2 discloses compressed solid oral dosage forms, e.g., by compaction of valsartan (optionally in salt form) optionally combined with HCTZ.
- the preferred range of cellulose is given 10 to 30%, e.g., 21%, for valsartan/HCTZ compositions and 5% valsartan alone.
- the preferred range of crospovidone is given as 10 to 20%, e.g., 13%.
- WO 0038676 A1 (NOVARTIS AG) 22.12.1999, page 24, lines 23-30 the application relates to a solid oral dosage form comprising valsartan as the active agent and microcrystalline cellulose wherein the weight ratio of valsartan to microcrystalline cellulose is from 2.5:1 to 0.3:1 , e.g., 2:1 to 1 :1 , e.g., 1.4:1.
- This application relates to a solid oral dosage form comprising valsartan as the active agent and more than 30% of microcrystalline cellulose by weight based on the total weight of the core components of said solid oral dosage form e.g., 31 to 65%, e.g., 50%.
- this application relates to a solid oral dosage form comprising valsartan as the active agent and microcrystalline cellulose wherein the weight ratio of valsartan to microcrystalline cellulose is from 2.5:1 to 0.3:1 , e.g., 2:1 to 1 :1 , e.g., 1.4:1
- the tablet material described in this application includes, apart from the valsartan active substance, optionally valsartan in combination with HCTZ, other additives, of which the most important one is suitably selected filler, which has a decisive importance for quality of the produced tablets.
- filler having a defined particle size and in defined amount.
- a preferable composition of the filler according to the invention WO 2005041941 A2 is microcrystalline cellulose having a particle size of 10 to 1000 ⁇ m, preferably 50 to 190 ⁇ m, especially preferably 90 ⁇ m, in amounts above 40 to 60% by weight, spray-dried anhydrous lactose having a particle size of 10 to 250 ⁇ m, preferably 150 to 250 ⁇ m, in amounts of 30 to 60%, compact lactose hydrate having particle size of 10 to 250 ⁇ m, in amounts 40 to 60% by weight, a polyalcohol selected from mannitol or sorbitol, which is compacted and has a particle size of 100 to 850 ⁇ m, preferably 200 to 400 ⁇ m, in amounts of 40 to 60% by weight, calcium hydrogen phosphate having particle size of 10 to 200 ⁇ m in amounts of 40 to 60% by weight, a combination of microcrystalline cellulose with lactose, preferably spray-dried anhydrous lactose, in a weight ratio of 1 :2 to 2:1 in amounts of 20 to 55%, and
- Summary of the Invention Objective of the present invention is to create a tablet containing valsartan as active ingredient, which has high powder flowability and easily divided into two or more pieces while being stable enough for transport and commercial use and that resists humidity for several days without taking up moisture or breaking apart if unblistered.
- Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water. In state of the art valsartan is micronized to obtain better dissolution. This process causes flowability problem in manufacturing. While in the state of the art tablets are known, said tablets have several disadvantages. Normally those tablets are very porous and thus not very hard. As a consequence they cannot be broken into two or more pieces, which renders them useless for regiments wherein only one half of a tablet shall be taken at a time. Additionally these porous tablets tend to be very sensitive to humidity. As a consequence they can not be stored for some days once the blister is opened.
- the present invention relates a pharmaceutical formulation in the form of a tablet consisting of
- the tabletting mixture includes substances that improve its flow properties.
- Microcrystalline cellulose and pregelatinized starch are the most advantageous substance for the described mixture in this invention; preferably in a weight ratio of microcrystalline cellulose to pregelatinized starch is greater than 0.1 and less than 1.0. This ratio is calculated by dividing the weight of microcrystalline cellulose to the weight of pregelatinized starch. Ratio of these substances is important for avoiding fluctuations of the tablet weight, caused by inappropriate flow of the solid mixture through the hopper into the high performance tabletting machine.
- the tablet has 80 mg to 320 mg valsartan.
- the tablet contains one or more filling and/or disintegrating agents. These agents are useful to produce tablets of a certain size and to support flowability step.
- the filling and/or disintegrating agents are microcrystalline cellulose and pregelatinized starch.
- the tablet also contains one or more lubricant or glidant. Lubricants and glidants are well known in the state of the art. Among them, the lubricant(s) are selected from the group of stearate, preferably magnesium stearate.
- the glidant(s) are selected from the group of silicon dioxide, preferably colloidal silicon dioxide.
- invention in the form of a tablet consisting of 20 to 34% of valsartan
- magnesium stearate 0.5 to 4.5% of magnesium stearate.
- the tablets that described in examples are produced by direct compression techniques.
- valsartan, microcrystalline cellulose, pregelatinized starch are mixed. Colloidal silicon dioxide are added to this powder and mixed. Then magnesium stearate are added to this powder and mixed. Finally, mixture is compressed by tablet compression machine.
- the present invention relates to tablet comprising valsartan as the active agent, microcrystalline cellulose and pregelatinized starch wherein the weight ratio of microcrystalline cellulose to pregelatinized starch is greater than 0.1 and less than 1.0.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a new pharmaceutical formulation in the form of a tablet consisting of valsartan as an active agent, pregelatinized starch, microcrystalline cellulose.
Description
VALSARTAN FORMULATIONS
Description
The present invention relates to a new pharmaceutical formulation in the form of a tablet consisting of valsartan as an active agent, pregelatinized starch, microcrystalline cellulose.
Background of the invention
Valsartan, a compound having the chemical name N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5- yl)[1 ,1 '-biphenyl]-4-yl]methyl]-L-valine, of formula I
Formula I
Valsartan belongs to the group of drugs that block receptors of angiotensin Il and thus cause a decrease of blood pressure. Presently valsartan tablets are marketed by Novartis as DIOVAN® in doses of 40, 80, 160 and 320 mg and it is used to treat hypertension.
WO 9524901 A1 (CIBA-GEIGY AG) 07.03.1995, page 6 is directed to the use of valsartan for the treatment of diabetic nephropathy. A hard gelatine capsule comprising valsartan is disclosed.
In the international patent application WO 9524901 A1 (CIBA-GEIGY AG) 07.03.1995, example 1 , a dosage capsule form is described of the following composition:
Valsartan 80 mg
Microcrystalline cellulose 110mg
Polyvidone K30 45.2mg
Sodium lauryl sulphate 1.2mg
Crospovidone 26mg
Magnesium Stearate 2.6mg
The described capsule dosage form above is prepared by below method. Valsartan and microcrystalline cellulose are granulated via wet granulation with solution of polyvidone and sodium lauryl sulphate in water. The granules are dried. Crospovidone and magnesium stearate are added to the dry granulate and the mixture is filled into capsules.
WO 9749394 A2 (NOVARTIS AG) 18.06.1997, page 14, example 1 :
Valsartan 80 mg
HCTZ 12.5mg
Aerosil 1.5mg
Microcrystalline cellulose 31.5mg
Crospovidone 20mg
Magnesium Stearate 4.5mg
The first fifth components above formulation are mixed and compacted at pressures 25 to 65 kN. The compacted material is further forced through a sieve. Granulate produced in this way is mixed with magnesium stearate and the mixture is compressed into tablets.
What is considered an extraordinary advantage of the production method of the cited application is the fact that for each specific formulation it is possible to find minimal necessary compacting pressure within the range of compacting pressures from 25 up to 65 kN, which results in obtaining a tablet having about six times faster disintegration rate than that obtained via usual compacting (i.e. using higher pressure).
WO 9749394 A2 (NOVARTIS AG) 18.06.1997, discloses compressed solid oral dosage forms, e.g., by compaction of valsartan (optionally in salt form) optionally combined with HCTZ. In this application, the preferred range of cellulose is given 10 to 30%, e.g., 21%, for valsartan/HCTZ compositions and 5% valsartan alone. The preferred range of crospovidone is given as 10 to 20%, e.g., 13%.
WO 0038676 A1 (NOVARTIS AG) 22.12.1999, page 24, lines 23-30 the application relates to a solid oral dosage form comprising valsartan as the active agent and microcrystalline cellulose wherein the weight ratio of valsartan to microcrystalline cellulose is from 2.5:1 to 0.3:1 , e.g., 2:1 to 1 :1 , e.g., 1.4:1. This application relates to a solid oral dosage form comprising valsartan as the active agent and more than 30% of microcrystalline cellulose by weight based on the total weight of the core components of said solid oral dosage form e.g., 31 to 65%, e.g., 50%.
WO 0038676 A1 page 24, lines 15-21 it has been found surprisingly that it is possible to improve the bioavailability characteristics of known solid formulations of valsartan by increasing the proportion of microcrystalline cellulose. It has also been found surprisingly that it is possible to improve the quality, e.g., better weight uniformity and better compression for the tablets, of said known solid formulations of valsartan by decreasing proportion of crosslinked PVP.
In further aspect, this application relates to a solid oral dosage form comprising valsartan as the active agent and microcrystalline cellulose wherein the weight ratio of valsartan to microcrystalline cellulose is from 2.5:1 to 0.3:1 , e.g., 2:1 to 1 :1 , e.g., 1.4:1
WO 2005041941 A2 (ZENTIVA A.S.) 02.11.2004, page 5, lines 26-32 and page 6, lines 1-5 the tablet material described in this application includes, apart from the valsartan active substance, optionally valsartan in combination with HCTZ, other additives, of which the most important one is suitably selected filler, which has a decisive importance for quality of the produced tablets. For ensuring the function of direct tabletting it is necessary to select filler having a defined particle size and in defined amount.
A preferable composition of the filler according to the invention WO 2005041941 A2 is microcrystalline cellulose having a particle size of 10 to 1000μm, preferably 50 to 190μm, especially preferably 90μm, in amounts above 40 to 60% by weight, spray-dried anhydrous lactose having a particle size of 10 to 250μm, preferably 150 to 250μm, in amounts of 30 to 60%, compact lactose hydrate having particle size of 10 to 250μm, in amounts 40 to 60% by weight, a polyalcohol selected from mannitol or sorbitol, which is compacted and has a particle size of 100 to 850μm, preferably 200 to 400 μm, in amounts of 40 to 60% by weight, calcium hydrogen phosphate having particle size of 10 to 200μm in amounts of 40 to 60% by weight, a combination of microcrystalline cellulose with lactose, preferably spray-dried anhydrous lactose, in a weight ratio of 1 :2 to 2:1 in amounts of 20 to 55%, and a combination
of microcrystalline cellulose and a polyalcohol, preferably a compacted polyalcohol, in a ratio of 1 :2, in amounts of 20 to 55%, based on the total weight of the formulation.
Summary of the Invention Objective of the present invention is to create a tablet containing valsartan as active ingredient, which has high powder flowability and easily divided into two or more pieces while being stable enough for transport and commercial use and that resists humidity for several days without taking up moisture or breaking apart if unblistered.
Description of the Invention
Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water. In state of the art valsartan is micronized to obtain better dissolution. This process causes flowability problem in manufacturing. While in the state of the art tablets are known, said tablets have several disadvantages. Normally those tablets are very porous and thus not very hard. As a consequence they cannot be broken into two or more pieces, which renders them useless for regiments wherein only one half of a tablet shall be taken at a time. Additionally these porous tablets tend to be very sensitive to humidity. As a consequence they can not be stored for some days once the blister is opened.
It has been found surprisingly that it is possible to improve physical stability of valsartan formulation by reducing the water activity of the formula by using microcrystalline cellulose and pregelatinized starch weight ratio. It has been also found surprisingly that it is possible to improve the flowability characteristics of known solid formulations of valsartan by using the proportion of microcrystalline cellulose and pregelatinized starch. A more surprisingly it is possible to improve the resistance to humidity.
The present invention relates a pharmaceutical formulation in the form of a tablet consisting of
• 20 to 34% (w/w) of valsartan as active agent, • microcrystalline cellulose and pregelatinized starch in a weight ratio of greater than 0.1 and less than 1.0,
• colloidal silicon dioxide,
• magnesium stearate the tablet being preparable by directly compressing the ingredients at a pressure of 70 N to 280 N.
In a further embodiment, the tabletting mixture includes substances that improve its flow properties. Microcrystalline cellulose and pregelatinized starch are the most advantageous substance for the described mixture in this invention; preferably in a weight ratio of microcrystalline cellulose to pregelatinized starch is greater than 0.1 and less than 1.0. This ratio is calculated by dividing the weight of microcrystalline cellulose to the weight of pregelatinized starch. Ratio of these substances is important for avoiding fluctuations of the tablet weight, caused by inappropriate flow of the solid mixture through the hopper into the high performance tabletting machine.
The tablet has 80 mg to 320 mg valsartan. The tablet contains one or more filling and/or disintegrating agents. These agents are useful to produce tablets of a certain size and to support flowability step. The filling and/or disintegrating agents are microcrystalline cellulose and pregelatinized starch. The tablet also contains one or more lubricant or glidant. Lubricants and glidants are well known in the state of the art. Among them, the lubricant(s) are selected from the group of stearate, preferably magnesium stearate. The glidant(s) are selected from the group of silicon dioxide, preferably colloidal silicon dioxide.
In a further aspect, invention relates a pharmaceutical formulation in the form of a tablet consisting of 20 to 34% of valsartan
20 to 29% of microcrystalline cellulose
8 to 50% of pregelatinized starch
0.5 to 6.0% of colloidal silicon dioxide
0.5 to 4.5% of magnesium stearate.
The tablets that described in examples are produced by direct compression techniques.
Firstly, valsartan, microcrystalline cellulose, pregelatinized starch are mixed. Colloidal silicon dioxide are added to this powder and mixed. Then magnesium stearate are added to this powder and mixed. Finally, mixture is compressed by tablet compression machine.
In a further aspect, the present invention relates to tablet comprising valsartan as the active agent, microcrystalline cellulose and pregelatinized starch wherein the weight ratio of microcrystalline cellulose to pregelatinized starch is greater than 0.1 and less than 1.0.
Example 1 (MCC:PS=0.9: 1):
Valsartan 320.0 mg
Microcrystalline cellulose (MCC) 279.0 mg
Pregelatinized starch (PS) 310.0 mg
Colloidal silicon dioxide 60.0 mg
Magnezyum stearate 31.0 mg
1000.0 mg
Example 2 (MCC:PS=0.7:1):
Valsartan 160.. O mg
Microcrystalline cellulose (MCC) 135.0 mg
Pregelatinized starch (PS) 191.O mg
Colloidal silicon dioxide 9.0 mg
Magnezyum stearate 5.0 mg
500.0 mg
Example 3 (MCC:PS=0.5:1):
Valsartan 80.0 mg
Microcrystalline cellulose (MCC) 67.5 mg
Pregelatinized starch (PS) 135.0 mg
Colloidal silicon dioxide 4.5 mg
Magnezyum stearate 2.5 mg
289.5 mg
Above formulations containing pregelatinized starch and microcrystalline cellulose show improved physical stability in this formulation due to its ability to reduce the water activity of the formula. In addition to these benefits, the results would show the strong flow functionality of pregelatinized starch and microcrystalline cellulose.
After exhaustive testing it has been found surprisingly that it is possible to improve the flowability characteristics of known solid formulations of valsartan wherein the weight ratio of microcrystalline cellulose to pregelatinized starch is greater than 0.1 and less than 1.0. It has also been found surprisingly that it is possible to improve the resistance to humidity.
It has been shown in Table 1 that better results are obtained by increasing pregelatinized starch amount in tablets.
Table 1. Results of loss on drying during stability
Above formulations containing pregelatinized starch and microcrystalline cellulose dissolved in max 6 minutes and consequently it has been showed that dissolution rates were increased (Table 2).
Table 2. Dissolution rate and disintegration time of valsartan tablet
Claims
1. A pharmaceutical formulation in the form of a tablet consisting of
• 20 to 34% (w/w) of valsartan as active agent, • microcrystalline cellulose and pregelatinized starch in a weight ratio of greater than 0.1 and less than 1.0,
• colloidal silicon dioxide,
• magnesium stearate the tablet being preparable by directly compressing the ingredients at a pressure of 70 N to 280 N.
2. The tablet according to claim 1 wherein the valsartan is present in an amount of between 80 and 320 mg of valsartan.
3. The tablet according to claim 1 consisting of
20 to 34% of valsartan
20 to 29% of microcrystalline cellulose
8 to 50% of pregelatinized starch
0.5 to 6.0% of colloidal silicon dioxide 0.5 to 4.5% of magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10726655A EP2405899A2 (en) | 2009-03-11 | 2010-03-10 | Valsartan formulations |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TRTR2009/01901 | 2009-03-11 | ||
| TR200901901 | 2009-03-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2010104485A2 true WO2010104485A2 (en) | 2010-09-16 |
| WO2010104485A3 WO2010104485A3 (en) | 2010-11-25 |
Family
ID=41226269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2010/000046 WO2010104485A2 (en) | 2009-03-11 | 2010-03-10 | Valsartan formulations |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2405899A2 (en) |
| WO (1) | WO2010104485A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2676660A1 (en) * | 2012-06-22 | 2013-12-25 | Sanovel Ilac Sanayi ve Ticaret A.S. | Compositions preventing hypertension comprising soluplus |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995024901A1 (en) | 1994-03-17 | 1995-09-21 | Ciba-Geigy Ag | Treatment of diabetic nephropathy with valsartan |
| WO1997049394A2 (en) | 1996-06-27 | 1997-12-31 | Novartis Ag | Sold oral dosage forms of valsartan |
| WO2000038676A1 (en) | 1998-12-23 | 2000-07-06 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| WO2005041941A2 (en) | 2003-11-03 | 2005-05-12 | Zentiva, A.S. | Valsartan containing formulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066961A1 (en) * | 2004-12-24 | 2006-06-29 | Krka, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| US20090215756A1 (en) * | 2005-05-18 | 2009-08-27 | Combino Pharm, S.L. | Formulations containing losartan and/or its salts |
| GT200600371A (en) * | 2005-08-17 | 2007-03-21 | SOLID DOSE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD TO DO THE SAME | |
| AU2006307470A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Pharmaceutical formulation of losartan |
| WO2007049291A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Novel solid dosage forms of valsartan and rochlorothiazide |
| WO2007052307A2 (en) * | 2005-10-31 | 2007-05-10 | Lupin Limited | Stable solid oral dosage forms of valsartan |
| TR200703568A1 (en) * | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formulations |
-
2010
- 2010-03-10 EP EP10726655A patent/EP2405899A2/en not_active Ceased
- 2010-03-10 WO PCT/TR2010/000046 patent/WO2010104485A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995024901A1 (en) | 1994-03-17 | 1995-09-21 | Ciba-Geigy Ag | Treatment of diabetic nephropathy with valsartan |
| WO1997049394A2 (en) | 1996-06-27 | 1997-12-31 | Novartis Ag | Sold oral dosage forms of valsartan |
| WO2000038676A1 (en) | 1998-12-23 | 2000-07-06 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| WO2005041941A2 (en) | 2003-11-03 | 2005-05-12 | Zentiva, A.S. | Valsartan containing formulation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2676660A1 (en) * | 2012-06-22 | 2013-12-25 | Sanovel Ilac Sanayi ve Ticaret A.S. | Compositions preventing hypertension comprising soluplus |
| WO2013191668A1 (en) * | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010104485A3 (en) | 2010-11-25 |
| EP2405899A2 (en) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2955495C (en) | High dosage strength tablets of rucaparib | |
| EP1994926B9 (en) | Valsartan formulations | |
| JP2014024874A (en) | Compressed preparation | |
| KR101479824B1 (en) | Elution-stabilized preparation | |
| AU2013365715B2 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
| JP2020114834A (en) | Ceritinib formulation | |
| EP2067470A1 (en) | Pharmaceutical compositions containing valsartan and process for its preparation | |
| JP2014037356A (en) | Candesartan cilexetil oral formulation | |
| CA2609026A1 (en) | Formulations containing losartan and/or its salts | |
| WO2010104485A2 (en) | Valsartan formulations | |
| WO2020098904A1 (en) | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor | |
| JP2011136908A (en) | Solid preparation including angiotensin ii receptor antagonist and method of improving storage stability of angiotensin ii receptor antagonist in the solid preparation | |
| EP2379061B1 (en) | Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability | |
| CN102614188A (en) | Capsule containing valsartan, levoamlodipine and hydrochlorothiazide and preparing method thereof | |
| CZ2016785A3 (en) | A pharmaceutical composition comprising nilotinib and the method of its preparation | |
| SK50472005A3 (en) | Tablet containing valsartan prepared via direct tabletting | |
| EP2471520B1 (en) | Pharmaceutical compositions of levetiracetam | |
| JP2015063570A (en) | Orally disintegrable tablet | |
| RU2007147953A (en) | PHARMACEUTICAL RECIPES OF MICRONIZED (4-CHLOROPHENYL) [4- (4-pyridylmethyl) -phthalazin-1-yl] AND ITS SALTS WITH IMMEDIATE EXCESSION AND HIGH CONTENT | |
| BG108034A (en) | Pharmaceutical composition containing citalopram | |
| CZ297417B6 (en) | Valsartan containing pharmaceutical composition | |
| JP2005015363A (en) | Small clarithromycin tablet | |
| CZ294505B6 (en) | Tablet containing valsartan and prepared by direct tabletting | |
| CA2785920A1 (en) | Solid oral dosage form containing olmesartan medoxomil | |
| JP2009542806A (en) | Stable preparation comprising a combination of a moisture-sensitive drug and a second drug, and a method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10726655 Country of ref document: EP Kind code of ref document: A2 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011/08842 Country of ref document: TR |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2010726655 Country of ref document: EP |